Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EMA told to broaden access to ADRs

This article was originally published in Scrip

Executive Summary

The European Ombudsman has asked the European Medicines Agency to review its transparency policy so that the public may have access to suspected serious drug adverse reaction reports, regardless of the form in which they are held. The EMA has until 31 July to submit a response to the ombudsman, who investigates complaints about maladministration in European Union institutions or bodies.

You may also be interested in...



Pharma Snubs WHO Call To Pool COVID-19 Patents

Almost three dozen countries have shown support for the alternative mechanism put forward by the World Health Organization to ensure that IP issues do not stand in the way of providing access to COVID-19 medicines, vaccines and diagnostics to ‘all of humanity.’

EMA Creates Internal Repository To Support Regulatory Consistency

Regulatory and scientific discussions undertaken by the European Medicines Agency’s human medicines evaluation committee are finding their way into a new internal repository.

EMA Offers Simultaneous Review Of Products For EU And Non-EU Markets

Companies can have their EU centralized marketing authorization application and submission for an Article 58 opinion (on medicines for use in non-EU countries) reviewed in parallel by the European Medicines Agency. The simultaneous assessment can be helpful when drugs and vaccines are needed for both EU and non-EU populations.

Topics

UsernamePublicRestriction

Register

WI964856

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel